Carmine N. Stengone is CEO & President at Contineum Therapeutics, Inc. (CTNM). They have made 2 open-market trades across 2 companies since 2024, most recently 2026-09-08.
CIK 0001861519
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $5K since 2024, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CTNM | 17,217 | $122K |
| KPRX | 1,250 | — |
| Total | $122K |
Shares reported on the most recent Form 4, priced at the 2026-09-08 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTNM | SELL · 10b5-1 | 2026-09-08 | 2026-09-08 | $16.46 | $41K | -13.9% | -16.1% | — |
| CTNM | SELL · 10b5-1 | 2026-08-03 | 2026-08-03 | $16.01 | $40K | -4.2% | +7.6% | — |
| CTNM | SELL · 10b5-1 | 2026-07-08 | 2026-07-08 | $16.00 | $40K | -12.9% | -3.6% | -18.9% |
| CTNM | SELL · 10b5-1 | 2026-06-30 | 2026-07-01 | $16.01 | $160K | -4.1% | +1.9% | -28.7% |
| CTNM | SELL | 2026-02-24 | 2026-02-26 | $16.02 | $114K | -13.6% | -19.7% | -13.4% |
| CTNM | SELL · 10b5-1 | 2026-02-11 | 2026-02-13 | $16.00 | $6K | +9.4% | -7.3% | -1.8% |
| KPRX | BUY | 2024-09-11 | 2024-09-12 | $3.68 | $5K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.